John Reed, Sanofi R&D chief (Jeff Rumans)
May 13, 2020 10:11 AM EDT
R&D

Sanofi flash­es more PhI­II da­ta on new mul­ti­ple myelo­ma drug, set­ting up bat­tle with Darza­lex

Jason Mast

Editor

Two months af­ter nab­bing their first ap­proved can­cer drug in a decade, Sanofi an­nounced new late-stage da­ta bur­nish­ing the drug’s ef­fi­ca­cy in an­oth­er com­bi­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times